We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-15.04%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$185M
AUM Growth
-$43.2M
Cap. Flow
+$19.8M
Cap. Flow %
10.73%
Top 10 Hldgs %
66.67%
Holding
76
New
13
Increased
20
Reduced
16
Closed
22
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$9.46M
2
ZGNX
Zogenix, Inc.
ZGNX
+$5.9M
3
RCM icon
R1 RCM Inc. Common Stock
RCM
+$5.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.26M
5
AMRN icon
Amarin Corp
AMRN
+$4.88M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.55M
2
SAGE icon
Sage Therapeutics
SAGE
+$4.05M
3
ABT icon
Abbott
ABT
+$3.07M
4
MDT icon
Medtronic
MDT
+$2.65M
5
ANAB icon
AnaptysBio
ANAB
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.02%
2 Industrials 10.11%
3 Miscellaneous 2.35%
4 Real Estate 0.52%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
OPNT
51
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$201K 0.11%
+13,901
New +$227K
2018 Q4
0 quarters
NGNE icon
52
Neurogene
NGNE
$474M
$159K 0.09%
+3,686
New +$180K
2018 Q4
0 quarters
EPZM
53
DELISTED
Epizyme, Inc
EPZM
$157K 0.08%
25,449
-22,000
-46% -$168K
2018 Q1
3 quarters
CFMS
54
DELISTED
Conformis, Inc. Common Stock
CFMS
$49K 0.03%
5,474
+400
+8% +$6.73K
2018 Q2
2 quarters
ANAB icon
55
AnaptysBio
ANAB
$1.42B
– –
-22,524
Closed -$2.25M –
DVAX icon
56
DELISTED
Dynavax Technologies
DVAX
– –
-27,000
Closed -$335K –
IMUX icon
57
PUT
Immunic
IMUX
$93.9M
– –
-96
Closed -$10.5K –
IOVA icon
58
Iovance Biotherapeutics
IOVA
$6.29B
– –
-44,140
Closed -$497K –
KIDS icon
59
OrthoPediatrics
KIDS
$576M
– –
-19,600
Closed -$718K –
MDGL icon
60
Madrigal Pharmaceuticals
MDGL
$10.3B
– –
-9,400
Closed -$2.01M –
MDT icon
61
Medtronic
MDT
$121B
– –
-26,800
Closed -$2.65M –
PODD icon
62
Insulet
PODD
$9.84B
– –
-8,765
Closed -$929K –
SGMO icon
63
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-40,000
Closed -$678K –
SPY icon
64
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$808B
– –
-90,000
Closed -$26.2M –
VKTX icon
65
Viking Therapeutics
VKTX
$3.23B
– –
-25,000
Closed -$436K –
XRAY icon
66
Dentsply Sirona
XRAY
$1.72B
– –
-16,680
Closed -$631K –
MODN icon
67
DELISTED
MODEL N, INC.
MODN
– –
-72,283
Closed -$1.15M –
SPPI
68
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-40,000
Closed -$672K –
SPPI
69
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-60,000
Closed -$1.01M –
ISEE
70
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-149,100
Closed -$352K –
AGTC
71
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-14,500
Closed -$106K –
WMGI
72
DELISTED
Wright Medical Group Inc
WMGI
– –
-66,600
Closed -$1.93M –
FOMX
73
PUT
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-25,000
Closed -$143K –
DERM icon
74
DELISTED
Dermira, Inc.
DERM
– –
-40,018
Closed -$436K –
MLNT
75
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-5,296
Closed -$105K –
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Eversept Partners held 76 positions worth $185M, down 19% from $228M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Eversept Partners deployed $19.8M of net new capital in Q4 2018, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was Fate Therapeutics: 165,000 shares worth $2.12M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 79% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Merck, an estimated $7.55M trimmed.

  • Eversept Partners's largest Q4 2018 buy was Fate Therapeutics: 165,000 shares worth $2.12M.
  • Eversept Partners added most to GSK in Q4 2018, an estimated $9.46M increase.
  • Eversept Partners's biggest Q4 2018 reduction was Merck, cutting an estimated $7.55M.
  • Eversept Partners fully exited Medtronic in Q4 2018, selling an estimated $2.65M.
  • Eversept Partners's ten largest holdings make up 67% of its $185M portfolio in Q4 2018.
  • Eversept Partners opened 13 new positions and closed 22 in Q4 2018.
  • Eversept Partners's portfolio value fell 19% quarter-over-quarter to $185M.

Based on Eversept Partners's 13F filing for Q4 2018, filed 13 Feb 2019.